Every 10-Q that Merit Medical Systems Inc (MMSI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MMSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MMSI filings page.
Merit Medical Systems, Inc. (MMSI) reported third-quarter sales of $416.2 million, up 8.4% year over year, and net income of $42.3 million, versus $27.8 million. Nine-month sales were $1,217.0 million, up 8.5%, and net income was $122.1 million versus $90.5 million. Diluted EPS was $0.70 for the quarter and $2.03 for nine months, versus $0.46 and $1.49.
Quarterly therapeutic and foundational sales rose 14.0% and 5.7%. Gross profit as a percentage of sales was 48.2% in the quarter versus 48.5%, and 49.4% for nine months versus 48.4%. Nine-month operating cash flow was $175.2 million versus $198.9 million; cash, cash equivalents and restricted cash were $505.8 million at September 30, 2026.
Merit acquired View Point Medical on April 1, 2026, for $90 million plus $2.8 million in working-capital and other cash adjustments. Two deferred payments of $25 million each are due on the first and second anniversaries and may be accelerated if specified sales targets are met. Merit sold the DualCap product line for $28 million, recording a $12.5 million pretax gain. On October 13, 2026, Merit acquired Solo Pace for $45 million upfront, subject to customary adjustments, and settled $2.5 million of principal and accrued interest on loans it had issued.
Merit Medical Systems reported solid growth for the quarter and first half of 2026. Net sales reached $418.8 million for Q2 and $800.7 million year-to-date, up 9.5% and 8.5% from 2025. Gross profit margin improved to 51.4% in Q2, lifting income from operations to $60.4 million. Net income was $38.8 million for Q2 and $79.8 million for the first six months, with diluted EPS of $0.65 and $1.33, respectively.
Foundational products generated $281.0 million of Q2 revenue and therapeutic products $137.9 million, with strong growth in cardiac therapies and endoscopy platforms. Merit completed the View Point Medical acquisition for $137.3 million net of cash, following earlier Biolife and C2 CryoBalloon deals, and sold the DualCap product line for $28 million, recording a $12.5 million gain. Cash and cash equivalents were $448.7 million, with $736.3 million of convertible notes outstanding and no borrowings under the $700 million revolving credit facility.
Merit Medical Systems delivered higher profitability in the quarter ended March 31, 2026. Net sales rose to $381.9 million from $355.4 million, a 7.5% increase, with growth in both foundational and therapeutic product categories and across domestic and international markets. Gross margin held steady at 48.4%, while operating income increased to $44.2 million. Net income improved to $41.0 million, or $0.68 diluted EPS, compared with $30.1 million, or $0.49 diluted EPS, a meaningful step-up in earnings. Cash, cash equivalents and restricted cash reached $490.2 million, and the company reported strong liquidity with over $697 million of additional borrowing capacity on its revolving credit facility. During the quarter, Merit completed the $28 million sale of its DualCap product line, generating a $12.5 million pre-tax gain, and later announced a $140 million acquisition of View Point Medical to expand its tissue localization technologies.
Merit Medical Systems (MMSI) filed its Q3 2025 10‑Q, reporting higher sales and steady profitability. Net sales were $384,157,000, up from $339,845,000 a year ago. Gross profit reached $186,411,000 versus $157,535,000. Income from operations was $42,612,000 compared with $37,261,000. Net income was $27,755,000, slightly below $28,444,000 last year. Diluted EPS was $0.46 versus $0.48.
Year to date, net sales were $1,121,970,000 vs. $1,001,356,000, and operating cash flow rose to $198,861,000 from $152,055,000. Cardiovascular segment sales were $366,425,000 in the quarter (from $322,855,000), and Endoscopy was $17,732,000 (from $16,990,000).
Cash and cash equivalents were $392,457,000, with long‑term debt of $732,916,000 related to 3.00% Convertible Notes due 2029. The company had approximately $697,000,000 in additional available borrowings under its revolver. MMSI closed the Biolife acquisition for an upfront $120,000,000 plus $7,200,000 adjustments; Biolife products contributed about $6,600,000 in net sales since closing. The effective tax rate increased to 28.0% for the quarter, reflecting legislation enacted during the period. Shares outstanding were 59,290,248 as of October 28, 2025.